(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/13862 A2

(51) International Patent Classification[7]: A61K 39/395

(21) International Application Number: PCT/US01/25204

(22) International Filing Date: 10 August 2001 (10.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/224,723	11 August 2000 (11.08.2000)	US
60/224,722	11 August 2000 (11.08.2000)	US
60/279,079	23 March 2001 (23.03.2001)	US

(71) Applicant *(for all designated States except US)*: **FAVRILLE, INC.** [US/US]; Suite 100, 10835 Altman Row, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GOLD, Daniel, P.** [US/US]; 2244 El Amigo, Del Mar, CA 92014 (US). **SHOPES, Robert, J.** [US/US]; 1639 28th Street, San Diego, CA 92102 (US).


(74) Agents: **GUISE, Jeffrey, W.** et al.; Brobeck, Phleger & Harrison, LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY



(57) Abstract: The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the V_H or V_L region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding V_H and/or V_L regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprise chimeric proteins made specifically from particular B cells from a patient having B cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a B cell mediated pathology.

WO 02/13862 A2

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.